127 results on '"Dapagliflozin -- Reports"'
Search Results
2. HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
3. Type 1 Diabetes Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
4. Liver Fibrosis Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Pfizer, AstraZeneca, Gilead Sciences, Galmed R&D, Hepion Pharma, Conatus Pharma, HK inno.N Corp
5. Shanghai Jiao Tong University Details Findings in Diabetic Nephropathy (Integrative Atac-seq and Rna-seq Analysis Associated With Diabetic Nephropathy and Identification of Novel Targets for Treatment By Dapagliflozin)
6. Study Findings on Type 2 Diabetes Published by Researchers at Chosun University Hospital (Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled ...)
7. Investigators from Kaohsiung Chang Gung Memorial Hospital Release New Data on Renal Hypertension (Dapagliflozin-entresto Protected Kidney From Renal Hypertension Via Downregulating Cell-stress Signaling and Upregulating ...)
8. Statens Serum Institute Reports Findings in Heart Failure (SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study)
9. Some Diabetes Drugs May Lower Dementia Risk
10. Researchers from Brigham and Women's Hospital Detail New Studies and Findings in the Area of Heart Failure (Dapagliflozin In Heart Failure With Mildly Reduced or Preserved Ejection Fraction According To Polypharmacy Status)
11. Molecular & Clinical Sciences Research Institute Researcher Adds New Study Findings to Research in Sodium-Glucose Transporter 2 Inhibitors (Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin and empagliflozin-induced ...)
12. Researchers at Stanford University School of Medicine Have Published New Data on Chronic Kidney Disease (SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health)
13. Study Findings from Department of Internal Medicine Provide New Insights into Peritoneal Dialysis (Peritoneal Glucose Uptake Reduction By Sodium-glucose Co-transporter 2 Inhibitors In Clinical Peritoneal Dialysis)
14. Type 1 Diabetes Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
15. Chronic Kidney Disease Pipeline, FDA Approvals, Clinical Trials and Companies 2024 (Updated)
16. Dapagliflozin Reduces Serum Uric Acid in Advanced Chronic Kidney Disease
17. Research from Saglik Bilimleri Universitesi Yields New Data on Type 2 Diabetes (Short-Term Effect of Sodium Glucose Co - Transporter 2 Inhibitors on Routine Laboratory Examinations)
18. FARXIGA Market Insights and Advanced Forecast Report Reveal Critical Developments in Myocardial Infarction Treatment by 2032
19. Chronic Kidney Disease Competitive Landscape Report 2023 (Updated)
20. Diabetes drug benefits heart failure patients in a surprising way
21. Researchers from Peking University Describe Findings in Heme Oxygenase (Decyclizing) (Dapagliflozin Alleviates Diabetic Kidney Disease via Hypoxia Inducible Factor 1a/heme Oxygenase 1-mediated Ferroptosis)
22. Findings from National Cheng Kung University in the Area of Heart Failure Described (2024 Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure With Preserved Ejection Fraction)
23. Peking University Third Hospital Reports Findings in Diabetes Research (Evaluating the Safety and Efficacy of Sodium-Glucose Co-transporter 2 Inhibitors in Subjects with Prediabetes: A Protocol for a Randomized Controlled Trial)
24. STUDY: JARDIANCE SLOWS KIDNEY DISEASE
25. Benefits of Dapagliflozin in Heart Failure Similar for Men, Women
26. Combination Treatment Beneficial in Albuminuric CKD
27. Benefits of Dapagliflozin in Heart Failure Similar for Men, Women
28. Nephrologists Lag Behind Other Physicians in Prescribing SGLT2 Inhibitors
29. Chronic Kidney Disease Competitive Landscape Report 2023 (Updated) | Boehringer Ingelheim, Eli Lilly, Reata Pharma, Novo Nordisk, KBP Biosciences, AstraZeneca, Allena Pharma, and others
30. Chronic Kidney Disease Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 | Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, Prokidney, and others
31. Chronic Kidney Disease Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
32. Type 1 Diabetes Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
33. Research from An-Najah National University Hospital Broadens Understanding of Peritoneal Dialysis (Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function)
34. 'Carol Davila' University of Medicine and Pharmacy Researchers Have Provided New Study Findings on Proinsulin (Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems-A Literature Review)
35. Obafemi Awolowo University Reports Findings in Bioinformatics (Neomangiferin, a Naturally Occurring Mangiferin Congener, Inhibits Sodium-Glucose Co-transporter-2: An In silico Approach)
36. Over 50 Indian companies planning to launch sitagliptin combinations very soon for type-2 diabetes
37. Dapagliflozin Reduces CV Death, Heart Failure Worsening in HFpEF Patients
38. Dapagliflozin Reduces CV Death, Heart Failure Worsening in HFpEF Patients
39. Dapagliflozin Well Tolerated in COVID-19 Patients, Regardless of eGFR
40. Dapagliflozin Beneficial for Heart Failure, Regardless of Frailty
41. New Heart Failure Study Findings Recently Were Reported by Researchers at Brigham and Women's Hospital (Dapagliflozin In Patients With Heart Failure and Deterioration In Renal Function)
42. Acute Myocardial Infarction Treatment Market to Show Immense Growth at a CAGR of 7.7% During the Study Period 2019-2032, Predicts DelveInsight
43. Chronic Kidney Disease Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 76+ Companies are working to improve the Treatment of Space | Eli Lilly and Company, Reata Pharma, Novo Nordisk
44. NPPA extends price regulation on oxygen concentrators for six more months
45. Study Findings on Heart Failure Described by Researchers at Institute for Cancer Research and Treatment (IRCCS) (Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice)
46. New Obesity and Diabetes Research from Kalinga Institute of Medical Sciences Discussed (Cost-effective Analysis of Prescribed Oral Hypoglycemic Agents amongst Pre-obese and Obese Diabetic Patients in a Tertiary Care Hospital in Odisha)
47. Mansoura University Researchers Provide New Study Findings on Non-Alcoholic Fatty Liver Disease (Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus)
48. Researchers at University of Texas Medical Branch Report New Data on Type 2 Diabetes (Ticagrelor and Dapagliflozin Have Additive Effects In Ameliorating Diabetic Nephropathy In Mice With Type-2 Diabetes Mellitus)
49. Patent Issued for Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof (USPTO 11040961)
50. 50+ Active Companies working to Develop 50+ Pipeline Therapies for Chronic Kidney Disease Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.